Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

QURE DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

March 19, 2026

Toll Brothers Opens New Model Home at Regency at Ten Trails in Black Diamond, Washington

March 19, 2026

Pepper Lunch to Open New Phoenix Location at Dove Valley on March 26; First 50 Guests Receive Free Signature Beef Pepper Rice

March 19, 2026

Umar Zameer’s lawyer blasts ‘Trumpian’ demands for judge to apologize

March 19, 2026

Europa Village Announces “Pathway to Possibilities” Autism Acceptance Gala to Benefit National and Local Programs

March 19, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Ibogaine By David Dardashti Explains the Impact of Ibogaine Hydrochloride on Pain Receptors
Press Release

Ibogaine By David Dardashti Explains the Impact of Ibogaine Hydrochloride on Pain Receptors

By News RoomJanuary 18, 20245 Mins Read
Ibogaine By David Dardashti Explains the Impact of Ibogaine Hydrochloride on Pain Receptors
Share
Facebook Twitter LinkedIn Pinterest Email

Miami, FL, Jan. 18, 2024 (GLOBE NEWSWIRE) —  Ibogaine by David Dardashti sheds light on the relief of opiates from the administration of ibogaine hydrochloride. While opiates are commonly used to treat physical pain, they have been found to have a significant impact on emotional pain as well. Research suggests that opiates enhance the production of opiate receptors, creating interconnected pathways that regulate both physical and emotional pain. However, once a person stops taking the drug, the extra receptors begin to fade, leading to physical and emotional distress.

Short term opiates such as fentanyl, oxycodone, and hydrocodone cause opiate receptors to expand, long term opiates such as Suboxone and methadone, treat opiate addiction by creating a binding affinity to the receptors. These drugs create interconnected pathways that regulate both emotional and physical pain, providing relief to individuals struggling with opioid addiction.

However, the study also revealed that once a person stops taking Suboxone, the extra receptors begin to fade, leading to physical and emotional pain. This finding highlights the importance of proper medical supervision and support during the recovery process. It is likely that opiate receptors play a crucial role in regulating both physical and emotional pain, and their sudden decrease can cause significant distress to individuals in recovery.

According to the study, enhancing a person’s stress tolerance can also increase their resilience towards physical pain. This means that individuals who are able to handle emotional stressors are more likely to withstand physical pain. This finding is especially relevant in today’s fast-paced and high-stress society, where chronic stress has become a common issue. Furthermore, the study also suggests that engaging in physical fitness can also improve a person’s resilience towards emotional stressors. Regular exercise has been shown to reduce stress levels and improve mood, making individuals more equipped to handle emotional challenges. This highlights the importance of incorporating physical activity into one’s daily routine for not only physical health but also mental well-being.

Doctor Ashok Bharucha, lead researcher of the study, stated, “Our findings show that there is a strong connection between stress tolerance and physical pain resilience. This highlights the importance of managing stress levels and engaging in physical fitness to improve overall well-being.” This study serves as a reminder that taking care of one’s mental and physical health go hand in hand.

David Dardashti, a renowned expert in the field of addiction treatment, has introduced a groundbreaking approach to treating opiate addiction through the use of ibogaine. This innovative treatment protocol focuses on proper dosing and procedures used to eliminate all duplicated opiate receptors, rather than keeping them active like traditional methods such as Suboxone and Methadone. This not only helps individuals recover without having to undergo physical and emotional discomfort, but also stabilizes the brain and body, improving communication between physical and emotional pain. Having knowledge of this information offers the background needed to understand the true extent of ibogaine Hydrochloride.

Unlike traditional methods that focus on managing withdrawal symptoms and cravings, David Dardashti’s ibogaine treatment targets the root cause of addiction by eliminating all duplicated opiate receptors. This not only helps individuals recover without complete disorientation of the brain and body, but also stabilizes the functionality of the kappa mu, and sigma opiate receptors. These receptors function as electroconvulsive neuropathways. A smooth and stabilized electric current among these receptors enhances communication between both physical and emotional pain. This approach has been proven to be highly effective in helping individuals achieve long-term recovery from opiate addiction.

David Dardashti’s revolutionary approach to opiate addiction recovery has gained widespread recognition in the field of addiction treatment. With his innovative use of ibogaine, David Dardashti continues to change the landscape of addiction treatment and provide hope for those struggling with opiate addiction.

For more information on David Dardashti’s ibogaine treatment and its success in helping individuals overcome opiate addiction, please visit his website at www.ibogaineclinic.com or call 1-800-818-4511.

Ibogaine By David Dardashti is an ibogaine detox and research center. Newly found progress in treatment protocol is improved through each and every person who enters the facility.

 KISS PR Team and Partners:
“The information provided in this press release is for informational purposes only. This information does not constitute advice or any endorsement by KISS PR and its partners. KISS PR and its partners assume no responsibility for any decision made or action taken based on the information provided. Any action you take upon the information from this press release is strictly at your own risk. Always seek the source company issuing the press release for further information.”

Legal Disclaimer (Medical):
Disclaimer: The information provided in this press release is for informational purposes only and should not be construed as medical advice. Neither KISS PR or its partners are responsible for any decisions made based on this information. People making any decision related to their health and wellness should consult with a medical professional and the source company issuing the content.

Source Company: David Dardashti

City: Miami

Phone: 1-800-818-4511

Email: [email protected]

Ibogaine By David Dardashti offers information to those seeking help with addiction and mental health disorders.

  • Ibogaine By David Dardashti

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

QURE DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Toll Brothers Opens New Model Home at Regency at Ten Trails in Black Diamond, Washington

Pepper Lunch to Open New Phoenix Location at Dove Valley on March 26; First 50 Guests Receive Free Signature Beef Pepper Rice

Europa Village Announces “Pathway to Possibilities” Autism Acceptance Gala to Benefit National and Local Programs

RR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Richtech Robotics (RR) Investors of Securities Class Action Deadline on April 3, 2026

Marine Corps Enlisted Leaders Visit HII’s Ingalls Shipbuilding to Advance Veteran-to-Shipbuilding Workforce Pipeline

RGNX DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

METC DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ramaco Resources (METC) Investors of Securities Class Action Deadline on March 31, 2026

GEMI DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gemini Space Station (GEMI) Investors of Securities Class Action Deadline on May 18, 2026

Editors Picks

Toll Brothers Opens New Model Home at Regency at Ten Trails in Black Diamond, Washington

March 19, 2026

Pepper Lunch to Open New Phoenix Location at Dove Valley on March 26; First 50 Guests Receive Free Signature Beef Pepper Rice

March 19, 2026

Umar Zameer’s lawyer blasts ‘Trumpian’ demands for judge to apologize

March 19, 2026

Europa Village Announces “Pathway to Possibilities” Autism Acceptance Gala to Benefit National and Local Programs

March 19, 2026

Latest News

RR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Richtech Robotics (RR) Investors of Securities Class Action Deadline on April 3, 2026

March 19, 2026

Bob Barker’s rep speaks out on ‘Price Is Right’ on-set harassment allegations

March 19, 2026

Almost 40% of Canadian youth blow past recommended screen time: data

March 19, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version